Related Experiment Video
Updated: Aug 17, 2026
Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
Activity of azithromycin against cryptosporidia in immunosuppressed rats
1Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38101.
Abstract:
Dexamethasone-immunosuppressed rats infected with Cryptosporidium parvum were used to assess the macrolides azithromycin and spiramycin for anticryptosporidial activity. Azithromycin consistently prevented ileal infection, while spiramycin was ineffective. The anticryptosporidial activity of azithromycin was dose-related, 200 mg/kg/day being the minimum dose that prevented infection. Therapeutically, azithromycin eliminated an established overt infection of the small intestine in immunosuppressed rats, but the infection recurred after azithromycin treatment was stopped. These findings suggest that azithromycin is a potentially useful anticryptosporidial agent and that long-term continuous administration may be necessary to treat cryptosporidiosis in the immunocompromised host.
Insights
Azithromycin effectively treated Cryptosporidium parvum infections in rats, preventing intestinal disease. However, the infection recurred after treatment cessation, suggesting long-term use may be needed for immunocompromised patients.
Area of Science:
- Infectious Diseases
- Pharmacology
- Immunology
Background:
- Cryptosporidium parvum is an opportunistic parasite causing severe diarrhea in immunocompromised individuals.
- Effective therapeutic options for cryptosporidiosis, particularly in immunocompromised hosts, remain limited.
Purpose of the Study:
- To evaluate the anticryptosporidial activity of azithromycin and spiramycin in a rat model.
- To determine the dose-response relationship and therapeutic efficacy of azithromycin against Cryptosporidium parvum.
Main Methods:
- Dexamethasone-immunosuppressed rats were infected with Cryptosporidium parvum.
- Animals were treated with varying doses of azithromycin or spiramycin.
- Ileal infection and overall parasitic load were assessed.
Main Results:
- Azithromycin demonstrated significant anticryptosporidial activity, preventing ileal infection in a dose-dependent manner (minimum effective dose: 200 mg/kg/day).
- Spiramycin was found to be ineffective against Cryptosporidium parvum in this model.
- While azithromycin could eliminate established infections, relapse occurred post-treatment cessation.
Conclusions:
- Azithromycin shows promise as a therapeutic agent for cryptosporidiosis.
- Continuous, long-term administration of azithromycin may be required for sustained efficacy in immunocompromised hosts.
- Further research into optimal dosing and duration for treating cryptosporidiosis is warranted.
More Related Videos
06:49Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
